DexCom's SWOT analysis: CGM leader's stock poised for growth amid challenges

DexCom (DXCM) reported Q1 2025 sales of $1.04 billion, a 14% year-over-year increase, exceeding estimates by $19 million due to record new patient starts, though EPS slightly missed at $0.32 due to supply chain-impacted gross margins. The company reiterated its 2025 revenue guidance of $4.6 billion, representing 14% growth, supported by expanding PBM coverage expected to add 6 million lives by year-end and the upcoming launch of the G7 15-Day CGM system; however, supply chain issues and increased competition remain key challenges, with analysts maintaining a generally positive outlook.

Analysis

DexCom Inc. (DXCM) demonstrates a resilient growth profile amidst a complex operating environment, reporting Q1 2025 sales of $1.04 billion, a 14% year-over-year underlying increase that surpassed consensus estimates by $19 million, driven by a record number of new patient starts. Despite this top-line strength and a reiterated 2025 revenue guidance of $4.6 billion (projecting 14% YoY growth), earnings per share (EPS) for Q1 2025 slightly missed expectations at $0.32, a marginal 0.2% YoY decline, primarily attributed to lower gross margins stemming from supply chain challenges. These supply disruptions led to a one-time gross margin shortfall in Q1 and prompted a 250 basis point downward revision to the full-year gross margin forecast at the midpoint, now guided to 64%-65% (adjusted). Key strategic growth levers include the significant expansion of U.S. Pharmacy Benefit Manager (PBM) coverage, anticipated to add approximately 6 million covered lives by year-end 2025, and the upcoming H2 2025 launch of the G7 15-Day CGM system, which, while not expected to be a major sales driver initially, is projected to improve gross margins. The company is also aggressively targeting the Type 2 diabetes market, aiming to cover an additional 20 million non-insulin-using patients in 2025, and anticipates faster growth in international markets compared to the U.S. While DexCom maintains a strong market position, robust demand, and a healthy five-year revenue CAGR of 22%, it faces persistent supply chain issues, increasing competition, and the impact of rebates (though these are expected to lessen in 2025). InvestingPro data indicates the company maintains strong cash flows and a moderate debt-to-equity ratio of 1.14, and suggests the stock may be trading below its Fair Value.

Key Decisions for Investors

• Investors should monitor DexCom's ability to resolve supply chain issues and achieve its revised gross margin guidance of 64%-65% for FY2025, as this is critical for profitability improvement.
• Consider the significant growth potential from expanded PBM coverage and penetration into the Type 2 diabetes market against the near-term headwinds of supply constraints and competitive pressures.
• Evaluate the reiterated $4.6 billion revenue guidance for 2025; while conservative in the view of some analysts, achieving this target alongside margin recovery could present upside, especially given the stock's potential undervaluation according to InvestingPro.
• Closely track new patient acquisition rates and the uptake of the G7 15-Day CGM system post-launch for indications of sustained market leadership and margin enhancement.